Amitkumar Mehta

CD40 Agonist Antibodies in Cancer Immunotherapy

Platelet factor 4–induced T _H 1-T _reg polarization suppresses antitumor immunity

Macrophages in immunoregulation and therapeutics

Inflammation and tumor progression: signaling pathways and targeted intervention

Targeting apoptosis in cancer therapy

Broadening horizons: the role of ferroptosis in cancer

The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth

Heparin-Induced Thrombocytopenia

Clinical relevance of tumour-associated macrophages

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

Copper induces cell death by targeting lipoylated TCA cycle proteins

Heparin induced thrombocytopenia: review

Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type Peripheral T-Cell Lymphoma

SEA-CD40, a non-fucosylated CD40 agonist: Interim results from a phase 1 study in advanced solid tumors.